荷丹片联合阿托伐他汀治疗冠心病的临床研究

发布时间：2018-05-28 05:27

本文选题：冠心病 + 荷丹片　；参考：《辽宁中医杂志》2017年05期

【摘要】：目的:观察荷丹片联合阿托伐他汀治疗冠心病的临床治疗效果以其为临床诊疗提供参考。方法:分析2015年1月—2016年1月在我院接受诊疗的冠心病(稳定性心绞痛)患者的资料。依据治疗药物的不同将患者分为观察组(阿托伐他汀+荷丹片)及对照组(阿托伐他汀)。对比两组患者治疗期12个月内心绞痛的累积发生率并检测相关血液学指标的改变。结果:本研究共纳入观察组41例,对照组44例。观察组治疗期间心绞痛的累积发生率显著低于对照组(14.63%,6/41 vs 36.36%,16/44;Log-rankχ~2=5.619,P=0.018)。治疗后,观察组与对照组TC、TG、LDL-c水平均显著降低(P0.05),但观察组低于对照组患者(P0.05)。治疗后,两组患者治疗后HDL-c水平均显著升高(P0.05),但观察组高于对照组患者(P0.05)。治疗后,观察组与对照组CRP、MMP-1、PAPP-A水平均显著降低(P0.05),但观察组低于对照组患者(P0.05)。结论:联合使用荷丹片可显著降低冠心病患者心绞痛发作频率,可能与其调控血脂、抗炎及提高动脉粥样斑块稳定等疗效有关。
[Abstract]:Objective: to observe the clinical effect of Hedan tablet combined with Atto vastatin in the treatment of coronary heart disease. Methods: the data of patients with coronary heart disease (stable angina pectoris) treated in our hospital from January 2015 to January 2016 were analyzed. Patients were divided into observation group (Atto vastatin Hedan tablet) and control group (Atto vastatin). The cumulative incidence of angina pectoris and the changes of related hematologic indexes were compared between the two groups during 12 months. Results: the study included 41 cases in the observation group and 44 cases in the control group. The cumulative incidence of angina pectoris in the observation group was significantly lower than that in the control group (14.63 / 6 / 41 vs 36.36) during the treatment period. After treatment, the levels of TCU TGN LDL-c in both the observation group and the control group were significantly decreased, but the levels in the observation group were lower than those in the control group. After treatment, the level of HDL-c in the two groups was significantly higher than that in the control group, but the level of HDL-c in the observation group was higher than that in the control group. After treatment, the levels of MMP-1 and PAPP-A in the observation group and the control group decreased significantly, but the levels in the observation group were lower than those in the control group. Conclusion: combined use of Hedan tablet can significantly reduce the frequency of angina pectoris attack in patients with coronary heart disease, which may be related to its effect on regulating blood lipid, anti-inflammation and improving the stability of atherosclerotic plaque.
【作者单位】：济宁学院医院;山东巨野煤田中心医院;
【分类号】：R541.4

【相似文献】